Combining Immune-Related Genes For Delineating the Extracellular Matrix and Predicting Hormone Therapy and Neoadjuvant Chemotherapy Benefits In Breast Cancer.

Front Immunol · 2022 · PMC9331652 · PMID 35911730

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally significantno p-value reported

However, the American Joint Committee on Cancer (AJCC) stage did not indicate a significant difference in ECMI; there was only a marginally significant difference between patients in stage II and stage I ( Figure 3B ).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.